HEADER ANTIBIOTIC 23-JAN-97 1AA5 TITLE VANCOMYCIN COMPND MOL_ID: 1; COMPND 2 MOLECULE: VANCOMYCIN; COMPND 3 CHAIN: A, B; COMPND 4 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 ORGANISM_SCIENTIFIC: AMYCOLATOPSIS ORIENTALIS; SOURCE 4 ORGANISM_TAXID: 31958 KEYWDS GLYCOPEPTIDE, ANTIBIOTIC EXPDTA X-RAY DIFFRACTION AUTHOR P.J.LOLL,A.E.BEVIVINO,B.D.KORTY,P.H.AXELSEN REVDAT 7 15-NOV-23 1AA5 1 HETSYN LINK ATOM REVDAT 6 29-JUL-20 1AA5 1 COMPND REMARK SEQRES HETNAM REVDAT 6 2 1 LINK SITE ATOM REVDAT 5 19-OCT-16 1AA5 1 REMARK REVDAT 4 27-JUL-11 1AA5 1 HETATM REMARK REVDAT 3 13-JUL-11 1AA5 1 VERSN REVDAT 2 24-FEB-09 1AA5 1 VERSN REVDAT 1 20-AUG-97 1AA5 0 JRNL AUTH P.J.LOLL,A.E.BEVIVINO,B.D.KORTY,P.H.AXELSEN JRNL TITL SIMULTANEOUS RECOGNITION OF A CARBOXYLATE-CONTAINING LIGAND JRNL TITL 2 AND AN INTRAMOLECULAR SURROGATE LIGAND IN THE CRYSTAL JRNL TITL 3 STRUCTURE OF AN ASYMMETRIC VANCOMYCIN DIMER. JRNL REF J.AM.CHEM.SOC. V. 119 1516 1997 JRNL REFN ISSN 0002-7863 JRNL DOI 10.1021/JA963566P REMARK 2 REMARK 2 RESOLUTION. 0.89 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-93 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 0.89 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 4.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 80.0 REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : NULL REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.124 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.124 REMARK 3 FREE R VALUE (NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 17899 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.112 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.112 REMARK 3 FREE R VALUE (F>4SIG(F)) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 17479 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 160 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 50 REMARK 3 SOLVENT ATOMS : 55 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 255.40 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 158.00 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 3 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 2553 REMARK 3 NUMBER OF RESTRAINTS : 3647 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : NULL REMARK 3 ANGLE DISTANCES (A) : NULL REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.019 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : NULL REMARK 3 ZERO CHIRAL VOLUMES (A**3) : NULL REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : NULL REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : NULL REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.008 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.011 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.025 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : NULL REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: REFINEMENT WAS CARRIED OUT VS. F**2; REMARK 3 SIMILAR 1,2 AND 1,3 DISTANCE RESTRAINTS WERE APPLIED TO THE TWO REMARK 3 VANCOMYCIN MOLECULES. ALSO, RESTRAINTS WERE IMPOSED TO LIMIT REMARK 3 DEVIATIONS OF RINGS AND PEPTIDE BONDS FROM PLANARITY AND REMARK 3 DIFFERENCES IN ALONG-BOND COMPONENTS OF ADPS. ADPS FOR SOLVENT REMARK 3 WERE RESTRAINED TO BE APPROXIMATELY ISOTROPIC, AND ANTIBUMPING REMARK 3 RESTRAINTS WERE USED TO PREVENT SOLVENT WATER MOLECULES FROM REMARK 3 VIOLATING MINIMUM CONTACT DISTANCES. CONJUGATE GRADIENT LEAST REMARK 3 SQUARES WAS USED FOR MOST OF THE REFINEMENT, WITH BLOCKED LEAST REMARK 3 SQUARES AT THE END. REMARK 4 REMARK 4 1AA5 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY BNL. REMARK 100 THE DEPOSITION ID IS D_1000170583. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : APR-96 REMARK 200 TEMPERATURE (KELVIN) : 98 REMARK 200 PH : 4.6 REMARK 200 NUMBER OF CRYSTALS USED : 2 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : NSLS REMARK 200 BEAMLINE : X8C REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.85 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MADNES, PROCOR REMARK 200 DATA SCALING SOFTWARE : XSCALE REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 17899 REMARK 200 RESOLUTION RANGE HIGH (A) : 0.890 REMARK 200 RESOLUTION RANGE LOW (A) : 10.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 85.8 REMARK 200 DATA REDUNDANCY : 12.80 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.07600 REMARK 200 FOR THE DATA SET : 100.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 0.89 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 0.95 REMARK 200 COMPLETENESS FOR SHELL (%) : 69.3 REMARK 200 DATA REDUNDANCY IN SHELL : 5.60 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.14300 REMARK 200 FOR SHELL : 31.50 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: NULL REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: DIRECT METHODS REMARK 200 SOFTWARE USED: SHELXL-93 REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 57.53 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.90 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: CRYSTALS WERE GROWN BY MIXING EQUAL REMARK 280 VOLUMES OF A 25 MG/ML VANCOMYCIN SOLUTION AND 2.2 M NACL, 0.1 M REMARK 280 SODIUM ACETATE, PH 4.6 (RESERVOIR BUFFER) AND THEN SUSPENDING REMARK 280 THIS DROP OVER THE RESERVOIR. CRYSTALS WERE GROWN AT 293 K., REMARK 280 VAPOR DIFFUSION - HANGING DROP REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 43 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z+1/2 REMARK 290 3555 -Y+1/2,X+1/2,Z+3/4 REMARK 290 4555 Y+1/2,-X+1/2,Z+1/4 REMARK 290 5555 -X+1/2,Y+1/2,-Z+3/4 REMARK 290 6555 X+1/2,-Y+1/2,-Z+1/4 REMARK 290 7555 Y,X,-Z REMARK 290 8555 -Y,-X,-Z+1/2 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 32.92000 REMARK 290 SMTRY1 3 0.000000 -1.000000 0.000000 14.22500 REMARK 290 SMTRY2 3 1.000000 0.000000 0.000000 14.22500 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 49.38000 REMARK 290 SMTRY1 4 0.000000 1.000000 0.000000 14.22500 REMARK 290 SMTRY2 4 -1.000000 0.000000 0.000000 14.22500 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 16.46000 REMARK 290 SMTRY1 5 -1.000000 0.000000 0.000000 14.22500 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 14.22500 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 49.38000 REMARK 290 SMTRY1 6 1.000000 0.000000 0.000000 14.22500 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 14.22500 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 16.46000 REMARK 290 SMTRY1 7 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY2 7 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 8 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY2 8 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 32.92000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1370 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 2890 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -32.8 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 APPLY THE FOLLOWING TO CHAINS: B, D REMARK 350 BIOMT1 2 0.000000 -1.000000 0.000000 14.22500 REMARK 350 BIOMT2 2 1.000000 0.000000 0.000000 14.22500 REMARK 350 BIOMT3 2 0.000000 0.000000 1.000000 -16.46000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH A2015 LIES ON A SPECIAL POSITION. REMARK 400 REMARK 400 COMPOUND REMARK 400 VANCOMYCIN IS A TRICYCLIC GLYCOPEPTIDE. THE SCAFFOLD IS REMARK 400 A HEPTAPEPTIDE WITH THE CONFIGURATION D-D-L-D-D-L-L. IT IS REMARK 400 FURTHER GLYCOSYLATED BY A DISACCHARIDE MADE OF D-GLUCOSE REMARK 400 AND VANCOSAMINE. REMARK 400 HERE, VANCOMYCIN IS REPRESENTED BY GROUPING TOGETHER THE REMARK 400 SEQUENCE (SEQRES) AND THE TWO LIGANDS (HET) BGC AND RER. REMARK 400 REMARK 400 THE VANCOMYCIN IS GLYCOPEPTIDE, A MEMBER OF ANTIBIOTIC CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: VANCOMYCIN REMARK 400 CHAIN: A, B, C, D REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 COMPONENT_2: RESIDUE BGC REMARK 400 COMPONENT_3: RESIDUE RER REMARK 400 DESCRIPTION: VANCOMYCIN IS A TRICYCLIC GLYCOPEPTIDE, GLYCOSYLATED REMARK 400 BY A DISACCHARIDE (RESIDUES 8 AND 9) ON RESIDUE 4. REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O2 BGC D 1 O5 RER D 2 2.01 REMARK 500 C2 BGC D 1 C1 RER D 2 2.18 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 3 -69.08 -100.65 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1C0Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VANCOMYCIN COMPLEXED WITH 2-ACETOXY-D- REMARK 900 PROPANOIC ACID REMARK 900 RELATED ID: 1C0R RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VANCOMYCIN WITH D-LACTIC ACID REMARK 900 RELATED ID: 1FVM RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VANCOMYCIN COMPLEXED WITH DI-ACETYL-LYS-D-ALA- REMARK 900 D-ALA REMARK 900 RELATED ID: 1GAC RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF A82846B COMPLEXED WITH ITS CELL WALL REMARK 900 PENTAPEPTIDE FRAGMENT REMARK 900 RELATED ID: 1GHG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VANCOMYCIN AGLYCON REMARK 900 RELATED ID: 1PN3 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF TDP-EPI-VANCOSAMINYLTRANSFERASE GTFA COMPLEXD REMARK 900 WITH TDP AND DESVANCOSAMINYL VANCOMYCIN REMARK 900 RELATED ID: 1PNV RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF TDP-EPI-VANCOSAMINYLTRANSFERASE GTFA COMPLEXED REMARK 900 WITH TDP AND VANCOMYCIN REMARK 900 RELATED ID: 1QD8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VANCOMYCIN COMPLEXED WITH N-ACETYL GLYCIN REMARK 900 RELATED ID: 1RRV RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF TDP-VANCOSAMINYLTRANSFERASE GTFD COMPLEXED REMARK 900 WITH TDP AND DESVANCOSAMINYL VANCOMYCIN. REMARK 900 RELATED ID: 1SHO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VANCOMYCIN DBREF 1AA5 A 1 7 NOR NOR00681 NOR00681 1 7 DBREF 1AA5 B 1 7 NOR NOR00681 NOR00681 1 7 SEQRES 1 A 7 MLU OMZ ASN GHP GHP OMY 3FG SEQRES 1 B 7 MLU OMZ ASN GHP GHP OMY 3FG HET MLU A 1 31 HET OMZ A 2 21 HET GHP A 4 15 HET GHP A 5 17 HET OMY A 6 21 HET 3FG A 7 20 HET MLU B 1 24 HET OMZ B 2 21 HET GHP B 4 16 HET GHP B 5 17 HET OMY B 6 21 HET 3FG B 7 20 HET BGC C 1 21 HET RER C 2 26 HET BGC D 1 42 HET RER D 2 25 HET ACY A 11 8 HET CL A 21 1 HET CL A 22 1 HET CL B 21 1 HET CL B 22 1 HETNAM MLU N-METHYL-D-LEUCINE HETNAM OMZ (BETAR)-3-CHLORO-BETA-HYDROXY-D-TYROSINE HETNAM GHP (2R)-AMINO(4-HYDROXYPHENYL)ETHANOIC ACID HETNAM OMY (BETAR)-3-CHLORO-BETA-HYDROXY-L-TYROSINE HETNAM 3FG (2S)-AMINO(3,5-DIHYDROXYPHENYL)ETHANOIC ACID HETNAM BGC BETA-D-GLUCOPYRANOSE HETNAM RER VANCOSAMINE HETNAM ACY ACETIC ACID HETNAM CL CHLORIDE ION HETSYN BGC BETA-D-GLUCOSE; D-GLUCOSE; GLUCOSE HETSYN RER (1R,3S,4S,5S)-3-AMINO-2,3,6-TRIDEOXY-3-METHYL-ALPHA-L- HETSYN 2 RER ARABINO-HEXOPYRANOSE FORMUL 1 MLU 2(C7 H15 N O2) FORMUL 1 OMZ 2(C9 H10 CL N O4) FORMUL 1 GHP 4(C8 H9 N O3) FORMUL 1 OMY 2(C9 H10 CL N O4) FORMUL 1 3FG 2(C8 H9 N O4) FORMUL 3 BGC 2(C6 H12 O6) FORMUL 3 RER 2(C7 H15 N O3) FORMUL 5 ACY C2 H4 O2 FORMUL 6 CL 4(CL 1-) FORMUL 10 HOH *55(H2 O) LINK C MLU A 1 N OMZ A 2 1555 1555 1.35 LINK C OMZ A 2 N ASN A 3 1555 1555 1.33 LINK OH OMZ A 2 C5 GHP A 4 1555 1555 1.39 LINK C ASN A 3 N GHP A 4 1555 1555 1.32 LINK C GHP A 4 N GHP A 5 1555 1555 1.36 LINK C3 GHP A 4 OCZ OMY A 6 1555 1555 1.39 LINK O4 GHP A 4 C1 BGC C 1 1555 1555 1.41 LINK C GHP A 5 N OMY A 6 1555 1555 1.33 LINK C3 GHP A 5 CG1 3FG A 7 1555 1555 1.50 LINK C OMY A 6 N 3FG A 7 1555 1555 1.34 LINK C MLU B 1 N OMZ B 2 1555 1555 1.33 LINK C OMZ B 2 N ASN B 3 1555 1555 1.32 LINK OH OMZ B 2 C5 GHP B 4 1555 1555 1.40 LINK C ASN B 3 N GHP B 4 1555 1555 1.34 LINK C GHP B 4 N GHP B 5 1555 1555 1.34 LINK C3 GHP B 4 OCZ OMY B 6 1555 1555 1.38 LINK O4 BGHP B 4 C1 BBGC D 1 1555 1555 1.45 LINK O4 AGHP B 4 C1 ABGC D 1 1555 1555 1.41 LINK C GHP B 5 N OMY B 6 1555 1555 1.34 LINK C3 GHP B 5 CG1 3FG B 7 1555 1555 1.51 LINK C OMY B 6 N 3FG B 7 1555 1555 1.32 LINK O2 BGC C 1 C1 RER C 2 1555 1555 1.41 LINK O2 BBGC D 1 C1 RER D 2 1555 1555 1.10 LINK O2 ABGC D 1 C1 RER D 2 1555 1555 1.47 CISPEP 1 GHP A 5 OMY A 6 0 6.04 CISPEP 2 GHP B 5 OMY B 6 0 18.86 CRYST1 28.450 28.450 65.840 90.00 90.00 90.00 P 43 21 2 16 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.035149 0.000000 0.000000 0.00000 SCALE2 0.000000 0.035149 0.000000 0.00000 SCALE3 0.000000 0.000000 0.015188 0.00000 HETATM 1 N MLU A 1 10.127 8.826 -4.030 1.00 4.98 N HETATM 2 CN MLU A 1 10.446 10.141 -4.639 1.00 7.32 C HETATM 3 CA MLU A 1 8.858 8.812 -3.244 1.00 4.18 C HETATM 4 C MLU A 1 7.715 9.246 -4.189 1.00 3.80 C HETATM 5 O MLU A 1 7.547 8.688 -5.252 1.00 5.85 O HETATM 6 CB MLU A 1 8.552 7.426 -2.726 1.00 4.30 C HETATM 7 CG MLU A 1 9.587 6.788 -1.780 1.00 4.89 C HETATM 8 CD1AMLU A 1 9.125 5.395 -1.392 0.74 5.46 C HETATM 9 CD1BMLU A 1 10.667 6.044 -2.523 0.26 5.31 C HETATM 10 CD2AMLU A 1 9.835 7.620 -0.583 0.74 7.84 C HETATM 11 CD2BMLU A 1 8.866 5.876 -0.846 0.26 5.59 C HETATM 12 H MLU A 1 10.887 8.557 -3.424 1.00 7.47 H HETATM 13 HCN1 MLU A 1 11.271 10.077 -5.126 1.00 10.98 H HETATM 14 HCN2 MLU A 1 10.533 10.801 -3.948 1.00 10.98 H HETATM 15 HCN3 MLU A 1 9.740 10.396 -5.238 1.00 10.98 H HETATM 16 HA MLU A 1 8.925 9.440 -2.494 1.00 6.27 H HETATM 17 HB2 MLU A 1 8.440 6.837 -3.489 1.00 6.45 H HETATM 18 HB3 MLU A 1 7.701 7.460 -2.261 1.00 6.45 H HETATM 19 HG MLU A 1 10.432 6.702 -2.269 1.00 7.34 H HETATM 20 HD11AMLU A 1 8.972 4.876 -2.185 0.74 8.19 H HETATM 21 HD11BMLU A 1 8.184 6.367 -0.382 0.26 8.38 H HETATM 22 HD12AMLU A 1 8.311 5.457 -0.888 0.74 8.19 H HETATM 23 HD12BMLU A 1 9.487 5.511 -0.211 0.26 8.38 H HETATM 24 HD13AMLU A 1 9.801 4.971 -0.858 0.74 8.19 H HETATM 25 HD21AMLU A 1 10.127 8.494 -0.855 0.74 11.77 H HETATM 26 HD21BMLU A 1 11.298 5.684 -1.895 0.26 7.97 H HETATM 27 HD22AMLU A 1 10.515 7.210 -0.043 0.74 11.77 H HETATM 28 HD22BMLU A 1 11.118 6.647 -3.119 0.26 7.97 H HETATM 29 HD23AMLU A 1 9.025 7.698 -0.073 0.74 11.77 H HETATM 30 HD23BMLU A 1 10.274 5.329 -3.028 0.26 7.97 H HETATM 31 HN22 MLU A 1 10.062 8.136 -4.764 1.00 7.47 H HETATM 32 N OMZ A 2 6.894 10.223 -3.742 1.00 3.44 N HETATM 33 CA OMZ A 2 5.824 10.725 -4.588 1.00 3.72 C HETATM 34 C OMZ A 2 4.491 9.963 -4.459 1.00 3.04 C HETATM 35 O OMZ A 2 3.547 10.291 -5.161 1.00 3.76 O HETATM 36 CB OMZ A 2 5.544 12.254 -4.376 1.00 3.81 C HETATM 37 OC OMZ A 2 6.731 13.006 -4.505 1.00 4.29 O HETATM 38 CG OMZ A 2 4.868 12.532 -3.066 1.00 3.68 C HETATM 39 CD1 OMZ A 2 3.489 12.760 -3.038 1.00 4.01 C HETATM 40 CD2 OMZ A 2 5.577 12.564 -1.859 1.00 3.89 C HETATM 41 CE1 OMZ A 2 2.836 12.923 -1.830 1.00 4.46 C HETATM 42 CL OMZ A 2 1.135 13.234 -1.833 1.00 7.25 CL HETATM 43 CE2 OMZ A 2 4.904 12.695 -0.669 1.00 4.34 C HETATM 44 CZ OMZ A 2 3.523 12.845 -0.655 1.00 4.40 C HETATM 45 OH OMZ A 2 2.866 12.894 0.557 1.00 4.99 O HETATM 46 H OMZ A 2 7.005 10.548 -2.953 1.00 5.16 H HETATM 47 HA OMZ A 2 6.123 10.618 -5.515 1.00 5.58 H HETATM 48 HB OMZ A 2 4.935 12.542 -5.088 1.00 5.71 H HETATM 49 HC OMZ A 2 7.083 12.839 -5.227 1.00 6.44 H HETATM 50 HD1 OMZ A 2 3.009 12.801 -3.834 1.00 6.01 H HETATM 51 HD2 OMZ A 2 6.505 12.495 -1.863 1.00 5.83 H HETATM 52 HE2 OMZ A 2 5.375 12.684 0.132 1.00 6.50 H